Claims
- 1. A compound of the formula: ##STR187## wherein A is a carbonyl group;
- B is a group of the formula: ##STR188## (in which R.sub.11 and R.sub.12 are each lower alkyl group, or they are combined together to form a lower alkylene group;
- W is trimethylene, propylene, tetramethylene, 2-methyltrimethylene or 2-methyltetramethylene, or a lower alkenylene group, a lower alkynylene group or a lower alkylene group substituted with hydroxyl; and
- G is a benzoisothiazolyl group, a benzoisothiazolyl group substituted with a member selected from the group consisting of lower alkyl, lower alkoxy, halogen and halogenated lower alkyl or a group of the formula: ##STR189## (in which Y is an oxygen atom, a carbonyl group, a methylene group, a group of the formula: ##STR190## (in which m is an integer of 0, 1 or 2), a group of the formula: ##STR191## (in which R.sub.13 is a hydrogen atom, a lower alkyl group or a lower alkanoyl group) or a group of the formula: ##STR192## and Z is a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group), or its pharmaceutically acceptable salt.
- 2. The compound according to claim 1, wherein R.sub.11 and R.sub.12 are each a lower alkyl group.
- 3. The compound according to claim 1, wherein W is tetramethylene or either one of the following groups: --CH.sub.2 CH.dbd.CHCH.sub.2 --, --CH.sub.2 C.dbd.CCH.sub.2, --CH.sub.2 CH(OH)CH.sub.2 CH.sub.2 -- and --CH.sub.2 CH.sub.2 CH(OH)CH.sub.2 --.
- 4. The compound according to claim 1, wherein G is a group of the formula: ##STR193## (in which Y is a carbonyl group and Z is a halogen atom, a lower alkyl group or a lower alkoxy group), or a benzoisothiazolyl group or a benzoisothiazolyl group substituted with a member selected from the group consisting of lower alkyl, lower alkoxy, halogen and halogenated lower alkyl.
- 5. The compound according to claim 1, wherein B is a group of the formula: ##STR194## (in which R.sub.11 and R.sub.12 are each a lower alkyl group), W is a lower alkyl group, W is tetramethylene and G is a group of the formula: ##STR195## (in which Y is a carbonyl group and Z is a halogen atom).
- 6. The compound according to claim 1, wherein said pharmaceutically acceptable salt is a salt with an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, acetic acid, oxalic acid, citric acid malic acid, maleic acid, tartaric acid, and fumaric acid.
- 7. A pharmaceutical composition for the treatment of psychosis which comprises as an active ingredient a pharmaceutically effective amount of at least one compound as claimed in claim 1, and at least one pharmaceutically acceptable inert carrier or diluent.
- 8. A method for the treatment of psychosis which comprises administering to a person suffering from psychosis a pharmaceutically effective amount of at least one compound as claimed in claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
61-228795 |
Sep 1986 |
JPX |
|
Parent Case Info
This application is a divisional of copending application Ser. No. 100,824, filed on Sept. 25, 1987, now U.S. Pat. No. 4,812,461.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3106552 |
Grogan et al. |
Oct 1963 |
|
3171839 |
Rorig |
May 1965 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
100824 |
Sep 1987 |
|